Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Alveolar proteinosis
ADR ID BADD_A00156
ADR Hierarchy
22      Respiratory, thoracic and mediastinal disorders
22.01      Lower respiratory tract disorders (excl obstruction and infection)
22.01.02      Parenchymal lung disorders NEC
22.01.02.009      Alveolar proteinosis
10      Immune system disorders
10.04      Autoimmune disorders
10.04.04      Autoimmune disorders NEC
10.04.04.018      Alveolar proteinosis
Description A PULMONARY ALVEOLI-filling disease, characterized by dense phospholipoproteinaceous deposits in the alveoli, cough, and DYSPNEA. This disease is often related to, congenital or acquired, impaired processing of PULMONARY SURFACTANTS by alveolar macrophages, a process dependent on GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR. [MeSH]
MedDRA Code 10001881
MeSH ID D011649
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Alveolar proteinosis | Pulmonary alveolar proteinosis | Autoimmune pulmonary alveolar proteinosis | Pulmonary Alveolar Proteinosis | Alveolar Proteinosis, Pulmonary | Proteinosis, Pulmonary Alveolar | Pulmonary Alveolar Proteinoses | Alveolar Proteinoses, Pulmonary | Proteinoses, Pulmonary Alveolar
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00194Azacitidine0.000168%
BADD_D00318Busulfan0.000168%
BADD_D00551Cyclosporine0.000166%
BADD_D00589Dasatinib0.000280%
BADD_D00594Deferasirox0.001239%
BADD_D00858Everolimus0.000306%
BADD_D00879Fentanyl0.000211%
BADD_D01831Prednisolone0.000210%
BADD_D01834Prednisone0.000018%
BADD_D02028Sirolimus0.000268%
BADD_D02105Tacrolimus0.001782%
BADD_D02214Ticagrelor0.000952%
The 1th Page    1    Total 1 Pages